Sagitta Biotech: what changed
Sagitta Biotech
Largest movements
- Intangible fixed assets +€320,042
up €320,042 (+611%), from €52,347 to €372,389
- Cash +€106,439
up €106,439 (+256%), from €41,642 to €148,081
mainly Contributions, distributions and other (+€780,998) and Trade debts (+€287,822)
- Receivables within one year +€72,483
up €72,483 (+21.0%), from €345,588 to €418,072
of which Other amounts receivable: +€53,640
- Deferred charges and accrued income +€11,393
up €11,393 (+1,015%), from €1,123 to €12,515
- Contributions +€600,000
up €600,000 (+89.6%), from €670,000 to €1.3m
- Profit (loss) carried forward -€354,671
down €354,671 (-47.7%), from -€742,915 to -€1.1m
- Trade debts +€287,822
up €287,822 (+256%), from €112,414 to €400,236
- Other debts -€181,937
down €181,937 (-46.5%), from €390,920 to €208,983
- Investment grants +€180,998
new in 2025: €180,998
- Gross operating margin +€45,629
up €45,629 (+24.8%), from -€184,290 to -€138,661
- Staff costs +€10,356
up €10,356 (+6.3%), from €164,568 to €174,924
- Depreciation +€5,190
up €5,190 (+18.3%), from €28,318 to €33,508
- Other operating charges +€3,977
up €3,977 (+207%), from €1,925 to €5,901
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €466,690 | €981,671 | +€514,981 | +110% |
| Fixed assets | 21/28 | €78,338 | €403,003 | +€324,666 | +414% |
| Intangible fixed assets | 21 | €52,347 | €372,389 | +€320,042 | +611% |
| Tangible fixed assets | 22/27 | €25,991 | €30,614 | +€4,623 | +17.8% |
| Plant, machinery and equipment | 23 | €23,584 | €28,100 | +€4,516 | +19.2% |
| Furniture and vehicles | 24 | €2,407 | €2,514 | +€107 | +4.4% |
| Current assets | 29/58 | €388,353 | €578,668 | +€190,315 | +49.0% |
| Amounts receivable within one year | 40/41 | €345,588 | €418,072 | +€72,483 | +21.0% |
| Trade receivables | 40 | - | €18,843 | +€18,843 | |
| Other amounts receivable | 41 | €345,588 | €399,229 | +€53,640 | +15.5% |
| Cash at bank and in hand | 54/58 | €41,642 | €148,081 | +€106,439 | +256% |
| Deferred charges and accrued income | 490/1 | €1,123 | €12,515 | +€11,393 | +1,015% |
| Total equity and liabilities | 10/49 | €466,690 | €981,671 | +€514,981 | +110% |
| Equity | 10/15 | -€72,915 | €353,411 | +€426,327 | |
| Contributions | 10/11 | €670,000 | €1,270,000 | +€600,000 | +89.6% |
| Capital | 10 | €670,000 | €1,270,000 | +€600,000 | +89.6% |
| Issued capital | 100 | €670,000 | €1,270,000 | +€600,000 | +89.6% |
| Profit (loss) carried forward | 14 | -€742,915 | -€1,097,587 | -€354,671 | -47.7% |
| Investment grants | 15 | - | €180,998 | +€180,998 | |
| Amounts payable | 17/49 | €539,606 | €628,260 | +€88,654 | +16.4% |
| Amounts payable within one year | 42/48 | €539,606 | €628,260 | +€88,654 | +16.4% |
| Financial debts | 43 | €4,703 | €2,503 | -€2,200 | -46.8% |
| Credit institutions | 430/8 | €4,703 | €2,503 | -€2,200 | -46.8% |
| Trade debts | 44 | €112,414 | €400,236 | +€287,822 | +256% |
| Suppliers | 440/4 | €112,414 | €400,236 | +€287,822 | +256% |
| Taxes, remuneration and social security | 45 | €31,569 | €16,537 | -€15,032 | -47.6% |
| Taxes | 450/3 | €369 | €0 | -€369 | -100% |
| Remuneration and social security | 454/9 | €31,200 | €16,537 | -€14,662 | -47.0% |
| Other amounts payable | 47/48 | €390,920 | €208,983 | -€181,937 | -46.5% |
| Accrued charges and deferred income | 492/3 | €0 | - | = | |
| Remuneration, social security and pensions | 62 | €164,568 | €174,924 | +€10,356 | +6.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €28,318 | €33,508 | +€5,190 | +18.3% |
| Other operating charges | 640/8 | €1,925 | €5,901 | +€3,977 | +207% |
| Gross operating margin | 9900 | -€184,290 | -€138,661 | +€45,629 | +24.8% |
| Operating profit (loss) | 9901 | -€379,100 | -€352,994 | +€26,106 | +6.9% |
| Financial income | 75/76B | €735 | €35 | -€700 | -95.2% |
| Recurring financial income | 75 | €735 | €35 | -€700 | -95.2% |
| Financial charges | 65/66B | €1,123 | €1,713 | +€589 | +52.5% |
| Recurring financial charges | 65 | €1,123 | €1,713 | +€589 | +52.5% |
| Profit (loss) for the period before taxes | 9903 | -€379,488 | -€354,671 | +€24,817 | +6.5% |
| Profit (loss) for the period | 9904 | -€379,488 | -€354,671 | +€24,817 | +6.5% |
| Profit (loss) for the period to be appropriated | 9905 | -€379,488 | -€354,671 | +€24,817 | +6.5% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 1 November 2026 via checked.be.